Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents : ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration

Autor: Pearson, ADJ, Zwaan, C.M., Kolb, EA, Karres, D, Guillot, J, Kim, SY, Marshall, L, Tasian, SK, Smith, M, Cooper, T, Adamson, PC, Barry, E, Benettaib, B, Binlich, F, Borgman, A, Brivio, E, Capdeville, R, Delgado, D, Faller, DV, Fogelstrand, L, Fraenkel, PG, Hasle, H, Heenen, D, Kaspers, G, Kieran, M, Klusmann, JH, Lesa, G, Ligas, F, Mappa, S, Mohamed, H, Moore, A, Morris, J, Nottage, K, Reinhardt, D, Scobie, N, Simko, S, Winkler, T, Norga, K, Reaman, G, Vassal, G

Publikováno v: European journal of cancer
Pearson, A D J, Zwaan, C M, Kolb, E A, Karres, D, Guillot, J, Kim, S Y, Marshall, L, Tasian, S K, Smith, M, Cooper, T, Adamson, P C, Barry, E, Benettaib, B, Binlich, F, Borgman, A, Brivio, E, Capdeville, R, Delgado, D, Faller, D V, Fogelstrand, L, Fraenkel, P G, Hasle, H, Heenen, D, Kaspers, G, Kieran, M, Klusmann, J H, Lesa, G, Ligas, F, Mappa, S, Mohamed, H, Moore, A, Morris, J, Nottage, K, Reinhardt, D, Scobie, N, Simko, S, Winkler, T, Norga, K, Reaman, G & Vassal, G 2020, ' Paediatric Strategy Forum for medicinal product development for acute myeloid leukaemia in children and adolescents : ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration ', European Journal of Cancer, vol. 136, pp. 116-129 . https://doi.org/10.1016/j.ejca.2020.04.038
European Journal of Cancer, 136, 116-129. Pergamon
European Journal of Cancer, 136, 116-129. Elsevier Ltd.

Purpose: The current standard-of-care for front-line therapy for acute myeloid leukaemia (AML) results in short-term and long-term toxicity, but still approximately 40% of children relapse. Therefore, there is a major need to accelerate the evaluatio

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::ea901e797ad2961db6c39007f2797adc
https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&origin=inward&scp=85087974955

Panobinostat plus bortezomib and dexamethasone in previously treated multiple myeloma: Outcomes by prior treatment

Autor: Richardson, P.G. Hungria, V.T.M. Yoon, S.-S. Beksac, M. Dimopoulos, M.A. Elghandour, A. Jedrzejczak, W.W. Guenther, A. Na Nakorn, T. Siritanaratkul, N. Schlossman, R.L. Hou, J. Moreau, P. Lonial, S. Lee, J.H. Einsele, H. Sopala, M. Bengoudifa, B.-R. Corrado, C. Binlich, F. San-Miguel, J.F.

Panobinostat is a potent pan-deacetylase inhibitor that affects the growth and survival of multiple myeloma (MM) cells through alteration of epigenetic mechanisms and protein metabolism. Panobinostat plus bortezomib and dexamethasone (PAN-BTZ-Dex) le

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=od______2127::de83bb13f333ecf36ccfab3d4a2c8675
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3001521

Impact of Treatment Duration and Dosing on Efficacy and Safety in a Phase 3 Study of Panobinostat Plus Bortezomib and Dexamethasone in Patients With Relapsed or Relapsed and Refractory Multiple Myeloma

Autor: San-Miguel, J.F., Hungria, V.T.M., Yoon, S.-S., Beksac, M., Dimopoulos, M.A., Elghandour, A., Jedrzejczak, W.W., Guenther, A., Nakorn, T.N., Siritanaratkul, N., Schlossman, R.L., Hou, J., Moreau, P., Lonial, S., Lee, J.H., Einsele, H., Sopala, M., Redhu, S., Paul, S., Corrado, C., Binlich, F., Richardson, P.G.

Publikováno v: In Clinical Lymphoma Myeloma and Leukemia September 2015 15 Supplement 3:e270-e271

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.